G-NiiB M3XTRA PRO Mechanism of Action

M3 CRC-Associated Bacteria: M3 CRC-associated bacteria involve a group of pathogenic bacteria and good bacteria which has shown correlation with colorectal adenoma and colorectal cancer. This group of bacteria has been developed into the M3CRC colorectal cancer prediction test with remarkably high sensitivity.
The role of gut dysbiosis in colorectal carcinogenesis has been increasingly recognised: The gut microbiome of CRC patients is different from that of healthy people.
The transfer of gut microbiota from CRC patients to germ-free mice promotes tumorigenesis in the latter.
Problematic gut microbiota potentially triggers inflammatory cascades and oncogenic signalling.
Gut Dysbiosis & Colorectal Cancer: Enrichment of certain bacterial species in the gut has been identified to contribute to colorectal carcinogenesis by promoting inflammation, causing DNA damage, inducing tumor proliferation and protecting tumor from immune attack.
Probiotics, such as Bifidobacteria and Streptococci are found to be depleted in CRC patients. These bacteria are suggested to exert a protective effect against CRC.
Potential Mechanisms of Probiotics: Action in the Prevention and Treatment of CRC: Colonization resistance: Probiotics inhibit colonization of pathogenic bacteria by releasing antimicrobial peptides, lowering luminal pH and/or directly interacting with pathogens.
Immunomodulation: Probiotics can have distinct immunomodulatory effect to reduce colonic inflammation or enhance antitumor immunity.
Enhancement of gut barrier function: Probiotics increase mucin production and tight junction protein expression and promote epithelial restitution.
Benefits demonstrated in patients: After taking M3XTRA PRO formula (SMT04) for 4 weeks: The level of CRC/adenoma-related bacteria decreased by 37.5%; the level of good bacteria increased by 42.6%; intestinal permeability decreased by 33.3%; restoring physiological barrier and preventing leaky gut.